Prevalence of Tuberculosis Infection among Various Risk Groups in India: A Systematic Review and Meta-Analysis

Author:

Chauhan Arohi1,Parmar Malik2,Dash Girish3,Solanki Hardik4,Chauhan Sandeep5,Sahoo Krushna Chandra6,Vadera Bhavin7,Rao Raghuram8,Kumar Ravinder8,Rade Kiran9,Pati Sanghamitra10

Affiliation:

1. Research Scientist, Public Health Foundation of India, New Delhi, India

2. National Professional Officer, Drug Resistant and Latent TB, WHO India, New Delhi, India

3. Health Technology Assessment Hub, Indian Council of Medical Research-Regional Medical Research Centre, Bhubaneswar, Odisha, India

4. National Consultant-Latent TB, Central TB Division, WHO NTEP Technical Support Network, New Delhi, India

5. National Consultant-Drug Resistant TB, Central TB Division, WHO NTEP Technical Support Network, New Delhi, India

6. Consultant (Public Health Specialist), Indian Council of Medical Research-Regional Medical Research Centre, Bhubaneswar, Odisha, India

7. Project Management Specialist, USAIDs, New Delhi, India

8. Central TB Division, Ministry of Health and Family Welfare, Government of India, New Delhi, India

9. International Technical Consultant, STOP TB Partnership, Geneva, Switzerland, India

10. Indian Council of Medical Research-Regional Medical Research Centre, Bhubaneswar, Odisha, India

Abstract

Abstract Treatment of tuberculosis (TB) infection (TBI) to prevent active TB disease is a key component of the National Strategic Plan to end TB in India, without which the strategies to end TB would be futile. There is a need to rapidly scale up access to effective shorter regimens for tuberculosis preventive treatment (TPT) to a wider set of risk groups. This applies for identifying high-risk groups for TPT expansion. Thus, our aim with this review is to determine the TBI prevalence in different risk groups in India. We searched databases like Embase, Medline, Scopus, and CINAHL for studies published between 2012 and 2023 to estimate TBI in different risk groups in India. The PRISMA guidelines were followed when reviewing the publications, and a predetermined search strategy was used to find relevant sources across various databases. Using MetaXL (MS excel) software, we pooled data based on a random-effects model, along with heterogeneity testing using Cochrane’s Q and I2 statistic. A total of 68 studies were included from 10,521 records. TBI pooled prevalence was estimated using the IGRA data, while in the absence of IGRA data, TST data were utilized. The key findings revealed a total of 36% pooled TBI prevalence for all risk factors, 59% among smokers, 53% among diabetics and alcoholics, 48% among malnourished, 47% among contacts of TB patients, 44% among HIV, 36% among pregnant women, 35% among COVID-19 patients, 31% among healthcare workers, 18% among sarcoidosis patients, and 15% among rheumatoid arthritis patients in India. Our review depicted a high TBI burden among groups such as diabetes mellitus, smokers, malnourished, and alcoholics. WHO has yet to recommend for systematic screening and treatment for TBI among these groups for want of evidence which this study provides, highlighting the need to reprioritize the risk groups for tailored TPT strategies.

Publisher

Medknow

Reference98 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3